Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 2/20 | 0.75 |
| ▸ | LMNA | P02545 | 2/20 | 0.75 |
| ▸ | MEN1 | O00255 | 2/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.75 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.75 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.73 |
| ▸ | GAA | P10253 | 1/20 | 0.73 |
| ▸ | BLM | P54132 | 1/20 | 0.73 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.73 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.73 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cicloprolol SCHEMBL9681296 | 0.96 | ADRB1 (0.80) | ADRB1LMNAMEN1KMT2ACYP2D6 | |
| Cicloprolol SCHEMBL9680771 | 0.96 | ADRB1 (0.80) | ADRB1LMNAMEN1KMT2ACYP2D6 | |
| Cicloprolol SCHEMBL634972 | 0.96 | ADRB1 (0.80) | ADRB1LMNAMEN1KMT2ACYP2D6 | |
| Cicloprolol SCHEMBL613271 | 0.95 | LMNA (0.81) | ADRB1LMNAMEN1KMT2ACYP2D6 | |
| Cicloprolol SCHEMBL22734881 | 0.95 | LMNA (0.81) | ADRB1LMNAMEN1KMT2ACYP2D6 | |
| Cicloprolol SCHEMBL613272 | 0.94 | ADRB1 (0.77) | ADRB1LMNAMEN1KMT2ACYP2D6 | |
| SCHEMBL11241308 | 0.90 | ADRB1 (0.93) | ADRB1LMNAMEN1KMT2ACYP2D6 | |
| SCHEMBL11242598 | 0.86 | ADRB1 (0.91) | ADRB1LMNAMEN1KMT2ACYP2D6 | |
| Betaxolol SCHEMBL23531 | 0.86 | ADRB1 (1.00) | ADRB1LMNAMEN1KMT2ACYP2D6 | |
| Betaxolol SCHEMBL6512495 | 0.86 | ADRB1 (1.00) | ADRB1LMNAMEN1KMT2ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4311708-A | ADRENERGIC BLOCKING AGENTS | SYNTHELABO (FR) | 1982-01-19 | — | — | US | claimed |
| CN-110831584-B | Targeted drug rescue with novel compositions, combinations and methods thereof | 埃克塞瓦有限责任公司 | 2023-03-10 | — | — | CN | disclosed |
| US-11478467-B2 | Targeted drug rescue with novel compositions, combinations, and methods thereof | Exciva GmbH (DE) | 2022-10-25 | — | — | US | disclosed |
| US-20200261442-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | VEPACHEDU SREENIVASARAO (US) | 2020-08-20 | — | — | US | disclosed |
| US-20200069674-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | Exciva GmbH (DE) | 2020-03-05 | — | — | US | disclosed |
| US-4311708-A | ADRENERGIC BLOCKING AGENTS | SYNTHELABO (FR) | 1982-01-19 | — | — | US | disclosed |
| US-4252984-A | 1-/P-/2-/CYCLOPROPYLMETHOXY/ETHYL/PHENOXY/-3-ISOPROPYLAMINO-2 -PROPANOL | SYNTHELABO (FR) | 1981-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11478467-B2 | Targeted drug rescue with novel compositions, combinations, and methods thereof | HTR2A, HTR2C, CYP3A43 | ADRB1 129/4885LMNA 1421/4885MEN1 3248/4885 |
| US-20200069674-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | HTR2A, HTR2C, CYP3A43 | ADRB1 129/4885LMNA 1421/4885MEN1 3248/4885 |
| US-20200261442-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | HTR2C, HTR2A, HTR3A | ADRB1 208/4885LMNA 2085/4885MEN1 3011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.